Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound that appeared to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus.
Nirmatrelvir is the main component of Pfizer’s PAXLOVID, which was recently authorized to treat COVID-19. PAXLOVID also includes ritonavir, which is an HIV drug.
Tags:
Source: Anixa Biosciences
Credit: